ClinicalTrials.gg
Not yet recruitingNCT07675434CESARUpdated Jun 30, 2026

Prospective Cohort of Acute Cardiology Referrals in an Ambulatory Day-Hospital Setting

An observational study in Acute Coronary Syndromes, Heart Failure and Pulmonary Embolism, Deep Vein Thrombosis, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
25,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Acute Coronary Syndrome by Assistance Publique - Hôpitaux de Paris — 5 open to participants now, 5 under way, 1 of them phase 3. Acute Coronary Syndrome · Assistance Publique - Hôpitaux de Paris.

Started
2026
the only one that year
Observational
8 of 19
3 open now
Registered
19th of 19
by date

Among the 19 studies in Acute Coronary Syndrome by Assistance Publique - Hôpitaux de Paris, this one is the only one that started in 2026, is one of 8 observational ones, and was the 19th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

5 of the 19 studies in Acute Coronary Syndrome by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Acute Coronary Syndrome by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Suspected acute or subacute cardiovascular diseases-including chest pain, dyspnea, and palpitations-are among the most common reasons for unscheduled emergency department visits and pre-hospital referrals. Despite this high clinical burden, the diagnostic yield is often limited, with a frequent mismatch between initial clinical suspicion and final diagnosis, contributing to substantial healthcare utilization and hospitalization rates. Current evidence is largely focused on specific conditions such as acute coronary syndromes, heart failure, arrhythmias, or pulmonary embolism, and rarely integrates the full spectrum of clinical, biological, and imaging data obtained during initial evaluation.

To address this gap, we will establish a prospective cohort of all consecutive patients referred to the ambulatory day-hospital cardiology unit at Lariboisière University Hospital. This unit acts as a specialized downstream referral structure within the emergency care pathway, receiving patients after triage by emergency physicians, pre-hospital regulation services (SAMU), mobile intensive care units (SMUR), or emergency departments. Although it does not capture all suspected cardiovascular emergencies, it represents a selected real-world population deemed to require specialized acute cardiology assessment.

The primary objective is to assess the frequency of cardiac conditions diagnosed in this cohort. Secondary objectives include characterization of patient profiles and diagnostic pathways; evaluation of the diagnostic and prognostic performance of clinical, biological, imaging, and multimodal parameters using final Heart Team diagnosis as reference; analysis of prior health history and healthcare utilization; and assessment of the medico-economic burden of suspected acute cardiovascular disease. The study will further support the development of a dedicated biobank and the validation of next-generation biomarkers, including AI-driven and voice-based markers, as well as decision-support algorithms for binary classification of cardiac involvement. Through integration of multimodal data and linkage with national health records, this approach aims to improve diagnostic accuracy, risk stratification, and understanding of the healthcare impact of acute cardiovascular presentations in a real-world setting.

03

Conditions studied

  • Acute Coronary Syndromes
  • Heart Failure
  • Pulmonary Embolism, Deep Vein Thrombosis
  • HTN-Hypertension
  • Arrhythmia

Keywords

  • Cardiovascular emergencies
  • Multimodality Imaging
  • Acute care
  • Prospective cohort
  • Biomarkers
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Consecutive patients referred to ambulatory day-hospital unit for suspicion of acute or sub-acute cardiovascular disease at the Cardiology Department of Lariboisière University Hospital.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- The study will include all consecutive patients referred to ambulatory day-hospital unit for suspicion of acute or sub-acute cardiovascular disease at the Cardiology Department of Lariboisière University Hospital.

Exclusion criteria

Exclusion Criteria:

  • Patient unable to provide
  • Patient not affiliated to French social security
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
25,000 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Proportion of patients with confirmed cardiovascular diagnosis among consecutive patients consulting for suspicion of acute or sub-acute cardiovascular disease at the ambulatory day-hospital unit.

    Time frame: From enrollement to six months of follow-up.

Secondary outcomes

  1. Proportion referred to cardiac computed tomography (CCT)

    Time frame: From enrollement to six months of follow-up.

  2. Proportion referred to cardiovascular magnetic resonance (CMR)

    Time frame: From enrollement to six months of follow-up.

  3. Proportion referred to stress tests.

    Time frame: From enrollement to six months of follow-up.

  4. Proportion referred to Holter monitoring or implantable loop recorders

    Time frame: From enrollement to six months of follow-up.

  5. Proportion with introduction of heart failure (HF) therapy

    Time frame: From enrollement to six months of follow-up.

  6. Proportion with introduction of anti-platelet therapy

    Time frame: From enrollement to six months of follow-up.

  7. Proportion with introduction of anti-coagulant therapy

    Time frame: From enrollement to six months of follow-up.

  8. Proportion referred to percutaneous coronary intervention (PCI)

    Time frame: From enrollement to six months of follow-up.

  9. Proportion referred to cardiac surgery

    Time frame: From enrollement to six months of follow-up.

  10. Proportion referred to electrical cardioversion

    Time frame: From enrollement to six months of follow-up.

  11. Proportion referred to catheter ablation

    Time frame: From enrollement to six months of follow-up.

  12. Proportion referred to pacemaker implantation

    Time frame: From enrollement to six months of follow-up.

  13. Proportion referred to defibrillator implantation

    Time frame: From enrollement to six months of follow-up.

  14. Diagnostic performance of each initial parameter with: sensitivity, specificity, positive predictive value, negative predictive value, and area under the ROC curve.

    Time frame: From enrollement to six months of follow-up.

  15. Cost of care pathways initial and up to 2-5 years

    Time frame: From enrollement to five years of follow-up.

  16. Prognostic value of baseline features to predict medical events annually up to 10 years of follow-up

    The occurrence of: 1. All-cause mortality 2. Cardiovascular mortality 3. Sudden cardiac death 4. Hospitalization for any cardiovascular reason and duration of hospitalization 5. Hospitalization for HF 6. Myocardial infarction (MI) 7. Stroke 8. Incident atrial fibrillation (AF) 9. Cardiac syncope 10. Incident ventricular arrhythmia 11. Cardiac surgery 12. Coronary revascularization including PCI and coronary artery bypass grafting (CABG) m. Valvular percutaneous intervention (TAVI, TMVI, mitral or tricuspid clips...) n. Electrophysiological studies (catheter ablation, pacemaker / defibrillator implantation...)

    Time frame: From enrollement to ten years of follow-up.

  17. Cost-effectiveness of the CESAR care pathway

    Cost-effectiveness of the CESAR care pathway compared with a propensity score-matched control population extracted from the French national health claims database.

    Time frame: From enrollement to five years of follow-up.

  18. F1 score of the artificial intelligence model for detecting cardiac involvement

    Time frame: From enrollement to six months of follow-up.

  19. Prognostic value of voice-derived acoustic and speech parameters

    The occurrence of: a. All-cause mortality b. Cardiovascular mortality c. Sudden cardiac death d. Hospitalization for any cardiovascular reason and duration of hospitalization

    Time frame: At enrollement (D0).

  20. Number of sick leave

    Time frame: From enrollement to five years of follow-up.

  21. Five-year event-free survival

    Event-free survival in patients managed through the CESAR care pathway compared with a propensity score-matched control population extracted from the French national health claims database.

    Time frame: From enrollement to five years of follow-up.

  22. Area under the precision-recall curve (PR-AUC) of the artificial intelligence model for detecting cardiac involvement

    Time frame: From enrollement to six months of follow-up.

  23. Area under the receiver operating characteristic curve (ROC-AUC) of the artificial intelligence model for detecting cardiac involvement

    Time frame: From enrollement to six months of follow-up.

  24. Duration of sick leave

    Cumulative duration of sick leave during follow-up in days.

    Time frame: From enrollement to five years of follow-up.

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Feb 2027, 6 months later.

Of 243 non-industry observational studies under Acute Coronary Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 71. This study's planned 6 months is below that.

Counting every sponsor, half of 277 studies reached it within 35 months; a quarter within 18 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2026
First posted
Jun 30, 2026
StartEst.
Aug 1, 2026
Primary completionEst.
Feb 1, 2027
CompletionEst.
Aug 1, 2041
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07675434
Collaborators
MIRACL.ai, INSERM UMR-S 942 MASCOT
Responsible party
Sponsor
First posted
Jun 30, 2026
Start date
Aug 1, 2026 (estimated)
Primary completion
Feb 1, 2027 (estimated)
Completion
Aug 1, 2041 (estimated)
Last update
Jun 30, 2026

Study contacts

Théo PEZEL, MD, PhD
Contact
theo.pezel@aphp.fr
+33 1 49 95 8224
Julien HUDELO, MD
Contact
juhudelo@gmail.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion